Phio Pharma Shares Shine After Positive PH-894 Preclinical Data At AACR Presentation
Phio Pharma Shares Shine After Positive PH-894 Preclinical Data At AACR Presentation
飛歐製藥在 AACR 演示會上呈陽性 PH-894 臨床前數據後股票大放異彩
Phio Pharmaceuticals Corp (NASDAQ:PHIO) has presented new preclinical data for PH-894, a self-delivering RNAi compound targeting the bromodomain-containing protein 4 (BRD4)
菲奧製藥公司(NASDAQ: PHIO) 提出了 PH-894 的新臨床前資料，這是一種針對含溴域蛋白 4 (BRD4) 的自我遞送 RNAI 化合物
- The preclinical data exhibited that PH-894 inhibits tumor growth in both PD-1 inhibition responsive and PD-1 inhibition insensitive models.
- The data will be presented at the American Association for Cancer Research (AACR) Annual Meeting.
- In both models, after local administration, strong antitumor efficacy was seen in directly treated and distal, untreated tumors.
- Also Read: Phio Pharma Shares Are Moving Higher On INTASYL Preclinical Data At ESMO Presentation.
- Additionally, intratumoral treatment with PH-894 enhanced the antitumor efficacy of systemic anti-PD-1 antibody therapy, not only for the PH-894 locally treated tumors but also for the PH-894 untreated distal tumors.
- In the PD-1 inhibition insensitive model, local PH-894 therapy was shown to be efficacious as a systemic anti-PD-1 antibody treatment and enhanced the antitumor efficacy of anti-PD-1 therapy when used together.
- Price Action: PHIO shares are up 59.9% at $1.45 during the market session on the last check Friday.
- 臨床前數據顯示，PH-894 在 PD-1 抑制反應和 PD-1 抑制抑制不敏模型中抑制腫瘤生長。
- 這些數據將在美國癌症研究協會（AACR）年會上公佈。
- 在這兩種模型中，局部給藥後，在直接治療和遠端未經治療的腫瘤中都可以看到強大的抗腫瘤功效。
- 另請閱讀： 在 ESMO 演示文稿上，Pio 製藥的股票在 INTASYL 臨床前數據上走高。
- 此外，使用 PH-894 進行的顱內治療增強了全身抗 PD-1 抗體治療的抗腫瘤功效，不僅適用於 PH-894 局部治療的腫瘤，還可以用於 PH-894 未經治療的遠端腫瘤。
- 在 PD-1 抑制不敏感模型中，局部 PH-894 療法被證明是一種全身性抗 PD-1 抗體治療的有效性，並在一起使用時增強了抗 PD-1 療法的抗腫瘤功效。
- 價格行動：在上次檢查週五的市場時段中，PHIO 股價上漲 59.9%，為 1.45 美元。